David Sidransky

Dr. Sidransky is a renowned oncologist and research scientist who was profiled by TIME magazine in 2001 as one of the top physicians and scientists in America. He is widely recognized for his work with early detection of cancer and the development of patient derived models for drug testing. Dr. Sidransky is a Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. He has authored more than 600 peer-reviewed publications, and has contributed to more than 65 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has been the recipient of numerous awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Hinda Rosenthal Award and 2017 Team Award presented by the American Association of Cancer Research. Dr. Sidransky was Vice Chairman of ImClone Systems until its acquisition by Eli Lilly for $6.5B in 2008. He founded several biotechnology companies, including Oncormed Pharmaceuticals and Champions Oncology, a developer of precision models for cancer therapy. He is chairman of the board of directors of Ayala and Advaxis and is a member of the BOD of Galmed, Ascentage pharma, and Orgenesis. In addition, Dr. Sidransky served as Director of The American Association for Cancer Research from 2005 to 2008. He received his B.A. from Brandeis University and his M.D. from the Baylor College of Medicine.